PHARMA

The long-term, higher value opportunity lies in developing a broad-spectrum antibiotic capable of combating a wide range of complicated hospital-acquired and community infections. MetalloBio intends taking a lead Series 1 compound, e.g. KLS-116 or one if its analogues, to Phase 2 clinical development before licensing it to a go-to-market company capable of conducting Phase 3 trials and marketing the resultant approved new antibiotic effectively. MetalloBio intends to design clinical studies to enhance the chances of switching at Phase 3 to a second complicated bacterial infection indication where possible, adding further value to the lead assets. 

MetalloBio welcomes discussions about direct commercial collaboration in a range of target indications which appear to be within the scope of MetalloBio’s compounds’ capabilities.

‍